Европейская академия естественных наук Hannover E.V.

Rongmin Yu

Rongmin Yu, male, born in Zibo, Shandong province, Ph.D, second-level professor, doctoral supervisor of Jinan University, China. He graduated from Shenyang College of Pharmacy as college student of pharmacy in 1982, and at the same college, he received his master degree of pharmacognosy in 1985 and doctor degree of natural medicinal chemistry in 1990.

Dr. Yu was engaged as associate researcher in 1993, senior visiting scholar invited by Kinki University, Japan in 1985-1986, professor in 1998 in Shenyang Pharmaceutical University. In 2002, Dr. Yu as talented person was engaged by Jinan University as professor, and after routine evaluation he was appointed as full professor of second-level in 2012. He has been appointed as Director of Biotechnological Institute of Chinese Materia Medica, Jinan University since 2011, and Chief Expert of Pharmaceutical Academy of Shandong Province since 2009.

Dr. Yu’s contributions in academy are mainly listed in the followings:

(1) In the beginning of 20th Century 1990s, he has focused on biosynthesis and biotransformation of natural bioactive constituents in Chinese Materia Medica (CMM) and natural medicines using the cutting-edge and frontier technology, such as: biotechnology, plant stem cells, PDNVs/PELNs (plant-derived nanovesicles or plant exosome-like nanoparticle), etc., including 15 medicinal plants (such as Ginkgo biloba L., Catharanthus roseus (L.) G. Don cv. Albus, Artemisia annua L., Polygonum multiflora Thunb., Panax quinquefolius L., Taxus wallichiana var. chinensis (Pilger) Florin, Camptotheca acuminata Decne.), and over 35 bioactive constituents (such as ginkgolides, vinblastine, vincristine, artemisinin, artemisinic acid, dihydroartemisinic acid, anthraquinones, paclitaxel, camptothecin, etc.) in these medicinal plants.

(2) Leading in the field of active macromoleculars from Arca genus in ocean CMMs, such as Arca inflata and A. subcrenata, Dr. Yu has achieved a series investigation achievements, and found 36 new proteins, polypeptides and polysaccharides, also screed their biological activities, proposed their possibility of potential pre-drugs.

(3) Dr. Yu and his colleagues gave their valuable international contribution in the research of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing: Contributing to SARS-CoV-2 clinical treatment, a drug library encompassing approximately 3,142 clinical-stage or FDAapproved small molecules (involving 1000 compounds obtained from CMM and natural medicines) is profiled to identify candidate therapeutic inhibitors targeting nucleocapsid protein (N) and spike protein (S) of SARS-CoV-2 by small-molecule microarrays in chips. Virtual screening is carried out in the N-terminal domain (N NTD), C-terminal domain (N-CTD) of N protein, and receptor-binding domain of S protein (S-RBD) in complex with these chip-screened compounds. Three antibiotics, ceftriaxone, cefotaxime, and cefuroxime showed enhanced binding affinity to all the target receptors, whereas cefotaxime and cefuroxime showed a high binding affinity towards S-RBD with angiotensin-converting enzyme 2 (ACE2) complex and share similar binding sites with RBD-ACE2. The platform elaborated here provides a common approach and could be extended for the screens of drugs against the emergency breakout novel virus. These molecules that are filtered out of the scope would also provide useful data for pharmacologists in future antivirus development. Representative research paper “The Study of Antiviral Drugs Targeting SARS-CoV-2 Nucleocapsid and Spike Proteins through Large-scale Compound Repurposing” has been selected as Best Paper Award by global top journal Cell Press in 2021.

During the past four decades, Dr. Yu has successively undertaken and completed more than 20 research projects, including two projects of National Major Science and Technology Projects/Major New Drug Creation, three projects of National Natural Science Foundation of China, Key Project of the Ministry of Education of China, etc. He has obtained 15 national invention patent authorizations. So far, Professor Yu has published more than 300 academic papers including 105 SCI papers as first or corresponding authors in important national and international journals. Edited and participated in the compilation of 21 monographs and textbooks including 9 books as chief editor and associate editor in which Natural Medicinal Chemistry (English edition) edited by Rongmin Yu and Huiming Hua is world’s first published as textbook in 2022. He has won seven prizes for provincial and ministerial levels, such as “Science and Technology Progress Achievement Award”, “Advanced Scientific and Technological Worker Achievement Award”, etc. Dr. Yu also achieved 15 national invention patents authorizations. He has been awarded some honorary title, such as “Outstanding Scientific and Technological Worker of Liaoning Province”， “Outstanding Expert of Industry-University-Research Collaboration in the Food and Medicine of Guangdong Province”, etc.

 

вверх

Энциклопедия ЕАЕН

 ¦  Impressum  ¦  Контакт